What happened to aptorum group?

NEW YORK & LONDON-- ( BUSINESS WIRE )--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023.

What is aptorum group?

Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas. Our principal office in Asia provides easy access to prosperous medical research resources and some of the world’s most talented specialists and clinicians.

What does aptorum stand for?

NEW YORK & LONDON, March 06, 2024 -- ( BUSINESS WIRE )--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company ( "Aptorum" ), and privately-held YOOV Group Holding Ltd. ( "YOOV") jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement" ).